Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Despite the beneficial effects of pirfenidone in treating idiopathic pulmonary fibrosis (IPF), it remains unclear if lung fibroblasts (FB) are the main therapeutic target. To resolve this question, we employed a comparative transcriptomic approach and analysed lung homogenates (LH) and FB derived from IPF patients treated with or without pirfenidone. In FB, pirfenidone therapy predominantly affected growth and cell division pathways, indicating a major cellular metabolic shift. In LH samples, pirfenidone treatment was mostly associated with inflammation-related processes. In FB and LH, regulated genes were over-represented in the Gene Ontology node “extracellular matrix”. We identified lower expression of cell migration-inducing and hyaluronan-binding protein (CEMIP) in both LH and FB from pirfenidone-treated IPF patients. Plasma levels of CEMIP were elevated in IPF patients compared to healthy controls and decreased after 7 months of pirfenidone treatment. CEMIP expression in FB was downregulated in a glioma-associated oncogene homologue-dependent manner and CEMIP silencing in IPF FB reduced collagen production and attenuated cell proliferation and migration. Cumulatively, our approach indicates that pirfenidone exerts beneficial effects via its action on multiple pathways in both FB and other pulmonary cells, through its ability to control extracellular matrix architecture and inflammatory reactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Liang, J., Zhang, Y., Xie, T., Liu, N., Chen, H., Geng, Y., Kurkciyan, A., Mena, J. M., Stripp, B. R., Jiang, D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4192 · Cited by 287
Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis
Taillé, C., Grootenboer-Mignot, S., Boursier, C., Michel, L., Debray, M.-P., Fagart, J., Barrientos, L., Mailleux, A., Cigna, N., Tubach, F., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0076oc · Cited by 120
Cited by
Human distal lung maps and lineage hierarchies reveal a bipotent progenitor
Kadur Lakshminarasimha Murthy, P., Sontake, V., Tata, A., Kobayashi, Y., Macadlo, L., Okuda, K., Conchola, A. S., Nakano, S., Gregory, S., Miller, L. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04541-3 · Cited by 344
Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
Roach, K., Castells, E., Dixon, K., Mason, S., Elliott, G., Marshall, H., Poblocka, M., Macip, S., Richardson, M., Khalfaoui, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.679388 · Cited by 39
Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?
Frohlich, J., & Vinciguerra, M. (2020) · GeroScience · doi:10.1007/s11357-020-00279-w · Cited by 28
Guo, H., Yang, J., Liu, S., Qin, T., Zhao, Q., Hou, X., & Ren, L. (2021) · Bioengineered · doi:10.1080/21655979.2021.1957645 · Cited by 7
Metadata
- Authors
- Kwapiszewska, G., Gungl, A., Wilhelm, J., Marsh, L. M., Thekkekara Puthenparampil, H., Sinn, K., Didiasova, M., Klepetko, W., Kosanovic, D., Schermuly, R. T., Wujak, L., Weiss, B., Schaefer, L., Schneider, M., Kreuter, M., Olschewski, A., Seeger, W., Olschewski, H., & Wygrecka, M.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2018-08-30
- Volume
- 52
- Issue
- 5
- Pages
- 1800564
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2889209983
- Cited by
- 80
- References
- 10
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1183/13993003.00564-2018
- The paper
- Kwapiszewska, G., Gungl, A., Wilhelm, J., Marsh, L. M., Thekkekara Puthenparampil, H., Sinn, K., Didiasova, M., Klepetko, W., Kosanovic, D., Schermuly, R. T., Wujak, L., Weiss, B., Schaefer, L., Schneider, M., Kreuter, M., Olschewski, A., Seeger, W., Olschewski, H., & Wygrecka, M. (2018). Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. European Respiratory Journal. https://doi.org/10.1183/13993003.00564-2018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.